Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Strasser

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Brain activation patterns elicited by the 'Faces Symbol Test' -- a pilot fMRI studyRh Grabner, F Popotnig, S Ropele, et al.
Pediatric Research|April 8, 2021
Neonatal outcomes during the COVID-19 pandemic in New York CityFelix Richter, Arielle S Strasser, Mayte Suarez-Farinas, et al.
Neurochemical Research|May 31, 2024
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating EffectsLaetitia Pouzol, Anna Sassi, Mélanie Tunis, et al.
Clinical Pharmacology and Therapeutics|January 6, 2021
A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement BiomarkerChristine Huynh, Andrea Henrich, Daniel S Strasser, et al.
Transplantation Proceedings|August 1, 1992
Fulminant hepatic failure and liver transplantationH Isai, A G Sheil, G W McCaughan, et al.
Nature Communications|August 21, 2024
Limb reduction in an Esco2 cohesinopathy mouse model is mediated by p53-dependent apoptosis and vascular disruptionArielle S Strasser, Ana Silvia Gonzalez-Reiche, Xianxiao Zhou, et al.
Clinical and Experimental Immunology|July 17, 2023
Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetesUrs Christen, Laetitia Pouzol, Mélanie Tunis, et al.
Experimental Lung Research|January 12, 2018
Granulomatous lung inflammation is nanoparticle type-dependentYves Pacheco, Marine Ponchon, Serge Lebecque, et al.
The Lancet. Rheumatology|November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trialAnca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
Molecular Genetics and Metabolism Reports|March 4, 2022
Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patientsRichard W D Welford, Herve Farine, Michel Steiner, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2008
Brain activation patterns elicited by the 'Faces Symbol Test' -- a pilot fMRI studyRh Grabner, F Popotnig, S Ropele, et al.
Pediatric Research|April 8, 2021
Neonatal outcomes during the COVID-19 pandemic in New York CityFelix Richter, Arielle S Strasser, Mayte Suarez-Farinas, et al.
Neurochemical Research|May 31, 2024
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating EffectsLaetitia Pouzol, Anna Sassi, Mélanie Tunis, et al.
Clinical Pharmacology and Therapeutics|January 6, 2021
A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement BiomarkerChristine Huynh, Andrea Henrich, Daniel S Strasser, et al.
Transplantation Proceedings|August 1, 1992
Fulminant hepatic failure and liver transplantationH Isai, A G Sheil, G W McCaughan, et al.
Nature Communications|August 21, 2024
Limb reduction in an Esco2 cohesinopathy mouse model is mediated by p53-dependent apoptosis and vascular disruptionArielle S Strasser, Ana Silvia Gonzalez-Reiche, Xianxiao Zhou, et al.
Clinical and Experimental Immunology|July 17, 2023
Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetesUrs Christen, Laetitia Pouzol, Mélanie Tunis, et al.
Experimental Lung Research|January 12, 2018
Granulomatous lung inflammation is nanoparticle type-dependentYves Pacheco, Marine Ponchon, Serge Lebecque, et al.
The Lancet. Rheumatology|November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trialAnca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
Molecular Genetics and Metabolism Reports|March 4, 2022
Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patientsRichard W D Welford, Herve Farine, Michel Steiner, et al.
Pageof 13